PRNewsWire
07 Jul 2026, 10:36 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
GRAIL's NHS-Galleri trial failed to meet its primary endpoint of a statistically significant reduction in Stage III-IV cancers. — Failure to meet a primary endpoint in a major trial for a core product directly undermines the company's value proposition and commercial viability.
-0.80A securities fraud class action lawsuit has been filed against GRAIL and its executives alleging they misled investors about the NHS-Galleri trial. — Legal proceedings create financial liability and reputational risk, though the primary driver of the stock drop was the trial failure itself.
-0.40GRAIL's stock price fell approximately 50.55% following the disclosure of the trial results. — The price drop is a lagging indicator of the fundamental failure, confirming significant market devaluation of the company's technology.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a securities fraud class action lawsuit and experienced a 50% stock price drop after failing to meet a primary clinical trial endpoint.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
10h ago
